Molecular Templates (MTEM)
(Delayed Data from NSDQ)
$1.64 USD
+0.09 (5.81%)
Updated Apr 24, 2024 03:57 PM ET
After-Market: $1.62 -0.02 (-1.22%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MTEM 1.64 +0.09(5.81%)
Will MTEM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MTEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MTEM
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)
Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know
MTEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for MTEM
Molecular Templates Inc Announces Layoffs, CMO Resignation
MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023
Biotech Alert: Searches spiking for these stocks today
Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals among healthcare movers
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism